Anlon Healthcare Limited — Investor Meet, 12-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Anlon Healthcare Limited held an earnings conference call to discuss its Q1 and FY26-27 financial performance. Management provided insights into the company's strategic transformation and future outlook.

**Financial Performance:**

Q1 FY27 saw total income surge to 87.62 Cr from 33.31 Cr YoY, driven by acquisitions and organic growth. EBITDA stood at 15.65 Cr (vs. 6.26 Cr YoY), and PAT was 8.28 Cr (vs. 3.55 Cr YoY). EBITDA margins moderated to ~17% due to rising raw material costs and integration expenses from the Remember India Health links acquisition. However, the company expects margins to recover to 25-30% by Q2/Q3 FY27 as input costs stabilize and integration benefits emerge.

**Management Commentary & Outlook:**

The company is evolving from an API manufacturer to an integrated pharmaceutical player, encompassing intermediates, APIs, custom manufacturing, finished dosage formulations, and industrial/fine chemicals. The acquisition of Remember India Health links marks entry into finished dosage formulations. Anlon aims for a ~30% revenue CAGR over the next three years, supported by expanded manufacturing capacity (1400-1600 MTPA), regulatory capabilities, and a diversified product portfolio. FY27 revenue is projected between 350-400 Cr, with potential to reach 700 Cr in FY28 driven by a new 130 Cr CAPEX expansion.

**Analyst Q&A Highlights:**

Management clarified that raw material price increases (2-3x for certain solvents) are still impacting margins, but price revisions are being implemented. EBITDA margins are expected to improve from Q2, with normalization by Q3. Remember India Health links is projected to contribute ~60 Cr revenue in FY27, with higher-than-25% EBITDA margins expected once operational. FY27 consolidated EBITDA margins are anticipated to be 25-27%. Anlon Biologics and Anlon Medicare are expected to start generating revenue from Q4 FY28 and Q2 FY28, respectively.

**Investor Angle:**

The company is navigating near-term margin pressures from raw material volatility and strategic acquisitions, while focusing on long-term growth and integration. Confidence in the revised strategy and future revenue targets is evident.